The use of rosiglitazone or bedtime insulin in the treatment of conventional oral anti-diabetic drug failure: a one-year randomized clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN33022160

Enrollment

110

Registered

2006-04-25

Start date

2000-01-10

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetic patients with conventional OAD failure Nutritional, Metabolic, Endocrine Diabetes

Interventions

Add-on with either rosigitazone or nocte insulin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chinese type 2 diabetic patients with conventional OAD failure

Exclusion criteria

Exclusion criteria: Type 1 diabetes

Design outcomes

Primary

Measure	Time frame
Glycaemic improvement	—

Secondary

Measure	Time frame
1. Lipid and blood pressure (BP) changes 2. Tolerability	—

Countries

Hong Kong

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026